fonda update

Brisbane, Australia 6th February 2012: Alchemia Limited (ASX:ACL) announces an update on
the sales performance of its marketed product, generic fondaparinux, which was launched in the US
in July 2011 by its worldwide marketing partner Dr Reddy’s Laboratories.
On Feb 3, Dr Reddy’s discussed the progress of fondaparinux during its third quarter results
presentation. The latest weekly data from US IMS Health shows that Dr Reddy's generic
fondaparinux reported prescription market share of 18%. This represents recent sales in excess of
$1.4m per week*. The retail segment of the market (non-hospital) is known to be relatively higher
priced and profitable compared with the non-retail (hospital) segment, and Dr Reddy’s has achieved
a dollar market share of over 30% in the retail segment. The dollar value of the retail market for
fondaparinux has remained robust at $240m (MAT) through 2011, maintained by a sharp increase
in prescription numbers after the introduction of lower price generics.
Commenting on the progress of generic fondaparinux, Alchemia’s CEO, Pete Smith said, “We are
very happy with the advances made by Dr Reddy’s both in terms of the market share achieved and
the increases in yields and production capacity. With this strong performance we believe that we are
on track to meet our expectations for fondaparinux in 2012”.
He added “With a strong balance sheet, the anticipated cashflow from fondaparinux and the recent
initiation of recruitment to our Phase III colorectal cancer and Phase II lung cancer trials, Alchemia
is well placed for a very exciting year.”
*Additional sales and market share data from Bloomberg/Wolters